Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teneligliptin/Canagliflozin combination in type 2 diabetes
NCT02220907Phase 3Completed
- Sponsor
- Mitsubishi Tanabe Pharma
- Start
- Aug 2014
- Primary completion
- Feb 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of canagliflozin in type 2 diabetes mellitus (T2DM), sponsored by Mitsubishi Tanabe Pharma. Started Aug 2014; status: completed.
02
Drugs
canagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02220907.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02220907.